Advertisement

Research Article Free access | 10.1172/JCI112450

Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.

L M Slater, P Sweet, M Stupecky, and S Gupta

Find articles by Slater, L. in: JCI | PubMed | Google Scholar

Find articles by Sweet, P. in: JCI | PubMed | Google Scholar

Find articles by Stupecky, M. in: JCI | PubMed | Google Scholar

Find articles by Gupta, S. in: JCI | PubMed | Google Scholar

Published April 1, 1986 - More info

Published in Volume 77, Issue 4 on April 1, 1986
J Clin Invest. 1986;77(4):1405–1408. https://doi.org/10.1172/JCI112450.
© 1986 The American Society for Clinical Investigation
Published April 1, 1986 - Version history
View PDF
Abstract

The development of drug resistance by tumor cells is a major obstacle to the cure of human malignancy. Cyclosporin A (CsA) completely reverses primary resistance to vincristine and cross resistance to daunorubicin in a pleiotropic drug-resistant subline of human T cell acute lymphatic leukemia. This subline is over 50-fold resistant to vincristine and fivefold resistant to daunorubicin. CsA has little effect on vincristine or daunorubicin activity in drug-sensitive parental leukemia and corrects daunorubicin resistance without altering cellular daunorubicin accumulation.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (April 1, 1986): No description
Advertisement
Advertisement